Cocrystal Pharma, Inc.宣布，其研发的抗病毒候选药物Cdi-988已获得美国食品药品监督管理局（FDA）授予的快速通道资格。该资格旨在加速Cdi-988针对诺如病毒感染的治疗及预防用途的开发和审评进程。
Cocrystal Pharma, Inc.宣布，其研发的抗病毒候选药物Cdi-988已获得美国食品药品监督管理局（FDA）授予的快速通道资格。该资格旨在加速Cdi-988针对诺如病毒感染的治疗及预防用途的开发和审评进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.